What should you know about angiosarcoma immunohistochemistry?

The result is interpreted alongside the cell pattern, tumour location, medical history, and imaging rather than as a positive-or-negative cancer test.

Pathologists usually assess several endothelial markers. CD31 and nuclear markers such as ERG can provide strong support for blood-vessel differentiation, while CD34 may be present in some tumours and absent in others. A stain for factor VIII-related antigen may also contribute, particularly in more clearly formed vascular areas.

No individual marker establishes angiosarcoma by itself. Some angiosarcomas can express cytokeratins, which are also found in carcinomas, and endothelial markers can occur in other lesions. The distribution and intensity of staining therefore matter, as do the tissue architecture and the quality of the sample. In selected clinical settings, additional stains or molecular testing may help separate angiosarcoma from benign vascular growths or other malignant tumours.

Review the final pathology diagnosis, not an isolated marker line. Check whether the report describes adequate tissue, the pattern of endothelial staining, and any remaining differential diagnoses. If wording such as “suspicious,” “indeterminate,” or “cannot exclude” appears, the treating team may request deeper sections, further stains, specialist pathology review, or another biopsy.

Bring the pathology report and relevant imaging to the consultation. Useful next steps depend on where the tumour arose and whether imaging shows disease elsewhere; they may include staging scans and discussion by a sarcoma-focused multidisciplinary team.

Contact the clinical team promptly if a mass, bruise-like skin area, swelling, or bleeding is enlarging or changing while you await results. After a biopsy, seek urgent medical assessment for bleeding that does not stop with firm pressure, rapidly increasing swelling, breathing difficulty, fainting, or signs of a severe allergic reaction. Report increasing redness, warmth, drainage, fever, or worsening pain because these can indicate a procedure-site infection.

Ask which stains support endothelial differentiation, which alternatives were excluded, and whether the sample was sufficient. You can also ask whether a sarcoma pathologist should review the slides, whether more tissue or molecular testing is needed, and how the pathology result will guide staging and treatment planning.